重要内容提示： 一、 董事会会议召开情况 益丰大药房连锁股份有限公司（以下简称"公司"）于 2026 年 3 月 25 日以 电子邮件方式发出第五届董事会第二十六次会议通知，会议于 2026 年 3 月 27 日在湖南省长沙市金洲大道 68 号益丰医药物流园五楼会议室以现场加通讯方式 召开，应参加表决的董事 9 人，实际参加表决的董事 9 人。本次会议的召集、召 开和表决程序符合有关法律、法规和《公司章程》的规定，会议形成的决议合法 有效。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-011 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 第五届董事会第二十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1. 《关于豁免本次董事会通知时限的议案》 由于本次董事会审议事项紧急，豁免本次董事会通知时限。 表决结果：9 票同意，0 票反对，0 票弃权。 2. 《关于聘任高级管理人员的议案》 二、 ...

益丰大药房连锁股份有限公司 关于聘任高级管理人员的公告 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-012 | | --- | --- | --- | | 证券代码：113682 | 证券简称：益丰转债 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 益丰大药房连锁股份有限公司（以下简称"公司"）因经营发展需要，根 据《公司法》《公司章程》的规定，经公司总裁高毅先生提名，公司于 2026 年 3 月 27 日召开董事会提名委员会与第五届董事会第二十六次会议，审议通 过《关于聘任高级管理人员的议案》，同意聘任李松峰先生为公司副总裁，任 期自本次董事会审议通过之日起至第五届董事会届满日止。 李松峰先生与公司董事及高级管理人员之间不存在关联关系，未受过中国 证监会及其他有关部门的处罚和证券交易所惩戒。其任职资格及推荐程序符合 《公司法》《公司章程》的相关规定。 李松峰先生简历详见附件。 特此公告。 益丰大药房连锁股份有限公司 董事会 2026 年 3 月 28 日 李松峰先生简历 李松峰 ...

证券研究报告 | 2026年03月26日 医药生物周报（25 年第 13 周） 优于大市 炎症靶点在心血管领域进展梳理 本周医药板块表现强于整体市场，医疗服务降幅居前。本周全部 A 股下 跌 3.42%（总市值加权平均），沪深 300 下跌 2.19%，中小板指下跌 3.86%，创业板指上涨 1.26%，生物医药板块整体下跌 2.77%，生物医 药板块表现强于整体市场。分子板块来看，化学制药下跌 2.08%，生物 制品下跌 1.79%，医疗服务下跌 4.32%，医疗器械下跌 4.00%，医药商 业下跌 4.01%，中药下跌 1.16%。医药生物市盈率（TTM）35.19x，处 于近 5 年历史估值的 77.27%分位数。 炎症靶点在心血管领域进展梳理。心血管疾病是全球第一大死因，从风 险因子及药物开发角度，第一梯队仍为 apoB/LDL-C 为代表的动脉壁内 沉积导致动脉粥样硬化形成，目前基于他汀、依折麦布、PCSK9 抗体 /siRNA 以及即将上市的口服 PCSK9 抑制剂等药物已形成较为完善的治 疗范式；第二梯队为 Lp(a)所代表的遗传性残余风险，多个候选管线处 于临床后期阶段；第三梯队为以 NLRP ...

20 Mar 2026 08:04:53 ET │ 39 pages China China's Burgeoning Silver Economy II: Healthcare & Insurance John Yung, CFA AC CITI'S TAKE Following the inaugural Super-Sector Analysis of our China Silver Economy series, which delved into the pension and lodging sectors, we focus on some of the largest & most compelling opportunities in this second installment: the symbiotic growth of healthcare and insurance. China's rapidly aging population presents significant, multi-decade growth opportunities for the two sect ...

S1130525060003 gantanhuan gjzq.com.cn 投资逻辑 受国际石油价格持续上涨及海外能源成本较高的影响，各类化工产品普遍迎来明显涨价，其中溶剂类产品由于其较难 囤货，市场报价持续走高，成为本轮化工品涨价中弹性最显著的品类之一，也直接带动医药中间体、原料药等下游行 业成本抬升。受到上游原材料成本提升影响，下游原料药产品或将迎来提价契机。从供给端看，由于原料药行业在 2020- 2022 年集中扩产，预计供给压力仍然存在，价格有望缓慢传导。从需求端看，下游客户自 23 年 4 月去库存，目前客 户库存水平已长时间处于较低位置。原料药价格已在低位运行较长时间，客户库存水平较低，一旦提价后预计会有较 好持续性，后续可关注价格提升带来的利润弹性。 药品：3 月 20 日，诺华宣布以 20 亿美元预付款及最高 10 亿美元里程碑付款，收购 Synnovation Therapeutics 旗下 泛突变选择性 PI3Kα抑制剂 SNV4818 及相关项目组合，强化 PI3Kα靶点差异化布局，聚焦突变选择性抑制剂在 HR+/HER2-乳腺癌领域的联用潜力，国内建议关注和黄医药 PI3K-ATTC ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行的审议程序：公司于 2025 年 4 月 15 日召开的第五届董事会第 十五次会议审议通过了《关于使用部分闲置募集资金委托理财的议案》，同 意在确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情 况下，使用最高额度不超过 30,000 万元募集资金进行委托理财，用于购买安 全性高、流动性好的理财产品，自董事会审议通过起 12 个月有效，在上述额 度与有效期限内，购买理财产品资金可循环滚动使用。公司监事会发表了同 意意见，保荐机构对该事项发表了核查意见。具体内容详见公司 2025 年 4 月 16 日披露于上海证券交易所官网（www.sse.com.cn）的《关于使用部分闲置 募集资金委托理财的公告》（公告编号：2025-032）。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-010 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关 ...

Core Insights - The report emphasizes the investment opportunities in the innovative drug industry chain and undervalued sectors within the pharmaceutical and biotechnology industry [1] - The investment rating is maintained at "Outperform the Market" [2] Group 1: Innovative Drug Development - Continuous progress in clinical development of innovative drugs is noted, with recent excellent clinical data from domestic innovative drugs presented at academic conferences, suggesting a focus on major academic meetings like ASCO in Q2 [4] - The trend of domestic innovative drugs expanding internationally continues, with multiple cooperation agreements indicating the recognition of China's R&D capabilities by multinational pharmaceutical companies [4] Group 2: CXO Industry Investment Opportunities - The CXO sector is identified as the strongest investment theme in the pharmaceutical sector, driven by improved international financing and a robust domestic innovative drug R&D environment [4] - Recommendations include companies such as WuXi AppTec, WuXi Biologics, and Kelun Pharmaceutical, which are expected to benefit from the growing demand in preclinical and clinical stages [4] Group 3: Home Medical Devices and Chain Pharmacies - The home medical device sector is projected to experience strong growth due to aging demographics and increased demand for popular products, with companies like Yuyue Medical and Sanofi Biologics highlighted for their strong positioning [4] - The retail pharmacy sector is expected to consolidate, with leading chain pharmacies like Yifeng Pharmacy and Dazhong Pharmacy likely to gain market share through effective supply chain management and acquisition capabilities [4] Group 4: Surgical Robotics Investment Opportunities - The National Healthcare Security Administration has introduced guidelines for pricing surgical and treatment assistance services, which may enhance the clinical application of intelligent innovative products [4] - Companies like MicroPort and Tianzhihang are noted for their advancements in surgical robotics and international market expansion [4] Group 5: Investment Portfolio - The investment portfolio includes A-shares such as Mindray Medical, United Imaging, and Aier Eye Hospital, as well as H-shares like CanSino Biologics and Hutchison China MediTech [4] Group 6: Industry Performance and Data Tracking - The pharmaceutical manufacturing industry reported a revenue of 24,870 billion yuan in 2025, with a slight decline of 1.2% year-on-year, while total profits increased by 2.7% to 3,490 billion yuan [8] - The retail sales of pharmaceuticals reached 7,294 billion yuan, reflecting a growth of 1.8% year-on-year [8] Group 7: Monthly Performance Review - The pharmaceutical sector experienced a slight decline of 0.18% in February, underperforming against the CSI 300 index [9] - The report indicates that the overall valuation of the pharmaceutical sector is relatively high, with a current PE (TTM) of 37.20, placing it in the 80.66% historical percentile [15]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][8]. Core Insights - The government work report has positioned biotechnology and pharmaceuticals as a new pillar industry, emphasizing the importance of innovation and development in this sector [2][11]. - The pharmaceutical and biotechnology sector has underperformed the overall market recently, with a decline of 2.78% compared to a 1.26% drop in the A-share market [1][21]. - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector is 36.18x, which is at the 78.6th percentile of its historical valuation over the past five years [1][26]. Summary by Sections Government Positioning - The government has upgraded the status of the biotechnology and pharmaceutical industry, highlighting its role in driving new productivity and technological innovation [2][11]. - Key development opportunities during the 14th Five-Year Plan include innovation, elderly care, openness, and strengthening basic healthcare services [13]. Market Performance - The overall A-share market saw a decline of 1.26%, with the biotechnology sector declining by 2.78% [1][21]. - Specific sub-sectors such as medical services and medical devices experienced significant declines, with medical services down 4.71% [1][21]. Valuation Metrics - The TTM price-to-earnings ratios for various sub-sectors are as follows: chemical pharmaceuticals at 43.80x, biological products at 45.58x, medical services at 32.48x, and medical devices at 39.48x [26]. Recommended Stocks - Major companies recommended for investment include: - Mindray Medical (300760.SZ): Strong in R&D and international expansion [30]. - United Imaging Healthcare (688271.SH): Focused on high-performance medical imaging and digital solutions [30]. - WuXi AppTec (603259.SH): A leading open-access drug development service platform [30]. - Aier Eye Hospital (300015.SZ): The largest eye care institution in China [30]. - Yuyue Medical (002223.SZ): A leading provider of medical devices and solutions [31].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The government work report has positioned biotechnology and pharmaceuticals as a new pillar industry, emphasizing the importance of innovation and development in this sector [2][11] - The pharmaceutical and biotechnology sector has underperformed the overall market recently, with a decline of 2.78% compared to a 1.26% drop in the A-share market [21] - The current price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology sector is 36.18x, which is at the 78.6th percentile of its historical valuation over the past five years [26] Summary by Sections Government Work Report - The report highlights the establishment of biotechnology and pharmaceuticals as a new pillar industry, with a focus on innovation and the development of new technologies such as artificial intelligence and quantum technology [2][11] - Key development opportunities during the 14th Five-Year Plan include innovation, elderly care, openness, and strengthening basic medical services [13] Market Performance - The overall A-share market saw a decline of 1.26%, with the biotechnology sector declining by 2.78%, indicating weaker performance compared to the broader market [21] - Specific declines were noted in various sub-sectors, including medical services down 4.71% and medical devices down 2.94% [21] Valuation Metrics - The P/E ratios for various sub-sectors are as follows: chemical pharmaceuticals at 43.80x, biological products at 45.58x, medical services at 32.48x, and medical devices at 39.48x [26] Recommended Stocks - Major companies recommended for investment include: - Mindray Medical (迈瑞医疗): A leader in medical devices with strong R&D and international expansion [30] - United Imaging Healthcare (联影医疗): Focused on high-performance medical imaging and digital solutions [30] - WuXi AppTec (药明康德): A comprehensive drug development service platform benefiting from global outsourcing trends [30] - Aier Eye Hospital (爱尔眼科): The largest eye care institution in China, leveraging international technology and management [30]

| 证券代码：603939 | 证券简称：益丰药房 公告编号：2026-008 | | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | 益丰大药房连锁股份有限公司 高级管理人员持股的基本情况 本减持计划实施前，益丰大药房连锁股份有限公司（以下简称"公司"）副总 裁王永辉先生持有公司股份 601,440 股（全部为无限售流通股），占公司总股本 比例 0.0496%；公司副总裁肖再祥先生持有公司股份 254,760 股（全部为无限售 流通股），占公司总股本比例 0.0210%。上述股份来源均为限制性股票激励计划 授予及资本公积金转增股本。 减持计划的实施结果情况 截至公告披露日，本次减持计划实施期间届满，公司收到王永辉先生、肖再 祥先生《减持股份结果告知函》，王永辉先生未减持公司股份，肖再祥先生累计 减持股份 60,000 股，占公司总股本 0.0049%。 | 股东名称 | 王永辉 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | ...